A business initiative involving the acquisition from Eagle Pharmaceuticals of exclusive development and commercialization rights in Japan for a liquid bendamustine formulation, including the TREAKISYM® RTD formulation, with the business continuing under an agreement involving an upfront payment, milestones and royalties.